Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558143 | 0.89 | TRPV1 (0.46) | TRPV1LMNAOPRM1RAB9ASMN1; SMN2 | |
| SCHEMBL5109897 | 0.87 | RAB9A (0.50) | TRPV1LMNAOPRM1RAB9ASMN1; SMN2 | |
| SCHEMBL5558398 | 0.82 | TRPV1 (0.43) | TRPV1LMNAOPRM1 | |
| SCHEMBL5111925 | 0.81 | LMNA (0.51) | TRPV1LMNARAB9AKMT2A | |
| SCHEMBL5118025 | 0.80 | TRPV1 (0.49) | TRPV1LMNAOPRM1 | |
| SCHEMBL5105662 | 0.80 | TRPV1 (0.49) | TRPV1LMNAOPRM1 | |
| SCHEMBL5111558 | 0.80 | TRPV1 (0.49) | TRPV1LMNAOPRM1 | |
| SCHEMBL5108222 | 0.76 | TRPV1 (0.45) | TRPV1LMNAOPRM1KMT2A | |
| SCHEMBL14421732 | 0.76 | TRPV1 (0.45) | TRPV1LMNAOPRM1KMT2A | |
| SCHEMBL13613593 | 0.75 | TRPV1 (0.52) | TRPV1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | claimed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | claimed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | claimed |
| EP-1594836-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | claimed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1594836-B1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1594836-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | TRPV1 31/4885LMNA 3474/4885OPRM1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.